A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer.
Trial Status Open
Aim To investigate the role of adjuvant chemotherapy with capecitabine following surgical resection of a biliary tract cancer.
BILCAP is an NCRN trial supported by Cancer Research UK.
If you are a Health Care Professional and would like access to the section of the site for Health Care Professionals and/or would like to be considered for participation as a Local Investigator for BILCAP, please contact us at BILCAP@trials.bham.ac.uk
The Clinical Trials Unit at the Cancer Research UK, Institute of Cancer Studies stands comfortably between the Pan Birmingham network of Hospitals that serve a population of over 5,000,000 people and a large basic science research group of over 200 researchers situated at the Institute of Cancer Studies
BILCAP protocol v8.0 [.pdf]
ASCO poster [.pdf]
ASCO Abstract
Trans-BIL program
In collaboration with Professors Andrew Beggs, Ian Tomlinson and John Primrose and Incyte, a multi-omic analysis of the BILCAP and other biliary tract cancer study material will be undertaken at the University of Birmingham. The intention is to describe the natural history of specific biliary tract genotypes as well as determine the predictive data sets for multidisciplinary treatment outcome.
This is under the supervision of the Trans-BIL study group and the Biliary Tract Cancer Virtual Tissue Bank (CRUK A20171). The work is due to start imminently.
For further details please contact John Bridgewater j.bridgewater@ucl.ac.uk
Related Links
AMMF The Cholangiocarcinoma Charity
Macmillan Cancer Support
Cancer Research UK